624 related articles for article (PubMed ID: 26272765)
1. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
[TBL] [Abstract][Full Text] [Related]
2. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.
Wang J; Lu Z; Yeung BZ; Wientjes MG; Cole DJ; Au JL
J Control Release; 2014 Mar; 178():79-85. PubMed ID: 24462901
[TBL] [Abstract][Full Text] [Related]
3. Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.
Cui M; Au JL; Wientjes MG; O'Donnell MA; Loughlin KR; Lu Z
J Urol; 2015 Jul; 194(1):230-7. PubMed ID: 25681288
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.
Wong HL; Shen Z; Lu Z; Wientjes MG; Au JL
Mol Pharm; 2011 Jun; 8(3):833-40. PubMed ID: 21417439
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
6. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
7. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
Yu YH; Kim E; Park DE; Shim G; Lee S; Kim YB; Kim CW; Oh YK
Eur J Pharm Biopharm; 2012 Feb; 80(2):268-73. PubMed ID: 22108492
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
9. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
10. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer.
Kala S; Mak AS; Liu X; Posocco P; Pricl S; Peng L; Wong AS
J Med Chem; 2014 Mar; 57(6):2634-42. PubMed ID: 24592939
[TBL] [Abstract][Full Text] [Related]
11. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
12. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel.
Liu C; Zhao G; Liu J; Ma N; Chivukula P; Perelman L; Okada K; Chen Z; Gough D; Yu L
J Control Release; 2009 Dec; 140(3):277-83. PubMed ID: 19699770
[TBL] [Abstract][Full Text] [Related]
13. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Yu H; Xu Z; Chen X; Xu L; Yin Q; Zhang Z; Li Y
Macromol Biosci; 2014 Jan; 14(1):100-9. PubMed ID: 23966347
[TBL] [Abstract][Full Text] [Related]
14. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
[TBL] [Abstract][Full Text] [Related]
15. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
Inoue M; Matsumoto S; Saito H; Tsujitani S; Ikeguchi M
Int J Cancer; 2008 Dec; 123(11):2696-701. PubMed ID: 18798274
[TBL] [Abstract][Full Text] [Related]
17. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
18. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
[TBL] [Abstract][Full Text] [Related]
19. Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes.
Yin T; Wang P; Li J; Wang Y; Zheng B; Zheng R; Cheng D; Shuai X
Biomaterials; 2014 Jul; 35(22):5932-43. PubMed ID: 24746965
[TBL] [Abstract][Full Text] [Related]
20. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression.
Jang YL; Yun UJ; Lee MS; Kim MG; Son S; Lee K; Chae SY; Lim DW; Kim HT; Kim SH; Jeong JH
Int J Pharm; 2012 Sep; 434(1-2):488-93. PubMed ID: 22613208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]